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Introduction {#sec1}
============

Intestinal helminth infections are highly prevalent in developing countries, with chronic infections causing significant host morbidity ([@bib19]). With the emergence of drug-resistant helminths, a limited number of effective anthelmintics, and stalling vaccine efforts, new therapeutic avenues require a better understanding of anti-helminth immunity and killing. Expulsion mechanisms of intestinal helminths have been widely studied and reported; however, the mechanism of helminth killing in the tissue prior to expulsion remain unclear. Upon infection, activated epithelial cells secrete a suite of alarmins, including interleukin (IL)-25, thymic stromal lymphopoietin (TSLP), and IL-33, which promote activation and differentiation of innate and adaptive immune cells, leading to type 2 inflammation ([@bib2], [@bib21], [@bib27], [@bib39]). IL-4-driven CD4^+^ T helper (Th)-2 cell differentiation, in combination with group 2 innate lymphoid cell (ILC2) activation, leads to the secretion of a suite of cytokines including IL-4, IL-5, IL-9, and IL-13, which propagate type 2 inflammation and activate the local stroma ([@bib13], [@bib14]). The resulting reorganization of intestinal tissue---with goblet cell hyperplasia, mucus hyper-secretion, and smooth muscle contraction ([@bib11], [@bib14], [@bib15], [@bib16], [@bib20], [@bib31])---alongside type 2 cytokine-driven immunological changes such as B cell class switching ([@bib27]) and alternate activation of macrophages ([@bib2]) contributes to parasite expulsion. However, the precise mechanism of parasite damage and killing, whether in tissue or lumen, has remained unclear.

Results and Discussion {#sec2}
======================

To identify local tissue responses and novel mechanisms of intestinal helminth killing during anti-helminth immunity, we used the natural mouse intestinal helminth *H. polygyrus* (*H.p.*). Following oral infection, stage 3 larvae (L3) migrate to the duodenum and proximal jejunum, where they penetrate the mucosae and embed into the *muscularis externa*, undergoing developmental moults before emerging into the lumen as adult worms ([@bib5], [@bib41]). C57BL/6 mice are naturally susceptible to a primary (1°) *H.p.* infection, establishing a chronic infection ([@bib34]). Following drug cure of a 1° infection (Rx), C57BL/6 mice are resistant to a secondary (2°) *H.p.* challenge infection ([@bib9]; model, [Figure 1](#fig1){ref-type="fig"}A). Resistance to *H.p.* 2° infection correlated with substantial inflammation and tissue remodeling ([Figure 1](#fig1){ref-type="fig"}B), and significantly more transcriptional activity in duodenal tissue than in 1° infection (*H.p.* 1°), with 665 genes differentially expressed in 2° infection compared to 145 genes in 1° infection and 116 common genes (relative to naive, 2-fold filter, p \< 0.05) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Using a ratio-of-ratios analysis to specifically identify genes expressed in resistant mice (*H.p.* 2°), we identified three transcriptional clusters based on their expression relative to uninfected mice and relative to susceptible mice (*H.p.* 1°) ([Figure 1](#fig1){ref-type="fig"}C, C1-C3; [Tables S1--S3](#mmc1){ref-type="supplementary-material"}). Cluster 1 (C1) identified common and quantitative differences between 1° and 2° infection, including several genes previously described in immunity to *H.p.* ([@bib2], [@bib17]). Cluster 2 (C2) identified qualitative differences between susceptible and resistant mice highlighting genes upregulated in *H.p.* 2° infection only. Many of these genes have not previously been described in immunity to *H.p.* Cluster 3 (C3) identified qualitative differences downregulated in *H.p.* 2° infection only. Pathway analysis reflected quantitative and qualitative transcriptional differences with a greater increase in immune-activated pathways in resistant mice, as previously described ([@bib1], [@bib3], [@bib26]), in addition to an increase in lipid metabolism pathways in *H.p.* 2° that was not previously described during anti-helminth immunity ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B). Increased activation of lipid metabolism pathways was also evident in resistant mice with or without a 2° challenge infection and was maintained for up to 48 days after drug treatment ([Figure 1](#fig1){ref-type="fig"}E), correlating with long-term resistance to reinfection following drug treatment ([@bib40]). Within C2 genes, which were upregulated in *H.p.* 2° infection only, we identified group 1B phospholipase A~2~, *Pla2g1b*, a member of a large family of secreted (sPLA~2~) enzymes that regulate lipid metabolism through hydrolysis of phospholipids ([@bib23], [@bib24]). *Pla2g1b* was significantly increased in drug-treated mice with or without challenge infection, correlating with lipid metabolism pathways and resistance to *H.p.* ([Figure 1](#fig1){ref-type="fig"}F). The enzymatic activity of PLA~2~ in the small intestine was marginally increased in susceptible mice but dramatically increased in resistant mice ([Figure S1](#mmc1){ref-type="supplementary-material"}C), reflecting a broad increase in several PLA~2~ enzymes in resistant mice ([Figure S1](#mmc1){ref-type="supplementary-material"}D).Figure 1*Pla2g1b* and Lipid Metabolism Correlate with Resistance to Intestinal Helminth Infection(A) C57BL/6 mice were orally infected with 200 L3 *H. polygyrus* (*H.p.*) larvae on day 0. A cohort of mice were sacrificed 7 days after 1° *H.p.* infection (*H.p.* 1°). Remaining mice were drug treated (Rx) on days 14 and 15. Mice were then reinfected with *H.p.* on day 35 or day 56 and harvested 7 days after infection (*H.p.* 2°).(B) H&E staining of the small intestine from *H.p.* 1° and *H.p.* 2° (D42).(C) Ratio-of-ratios analysis of differentially expressed genes in *H.p.* 1° and *H.p.* 2° (D42) identified distinct gene clusters (C1-3).(D) Top 10 pathways predicted to be activated more highly in and *H.p.* 2° than *H.p.* 1° (both relative to naive, 2-fold filter, p \< 0.05).(E) Lipid metabolism pathway predicted activation score (relative to naive, 2-fold filter, p \< 0.05).(F) *Pla2g1b* expression in small intestine from RNA sequencing data, confirmed by qPCR.Data are represented as mean ± SEM; n = 8, *^∗^ = p \<* 0.05, ^∗∗^ = p \< 0.01 determined using a one-way ANOVA with Dunnett's multiple comparison analysis. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Tables S1--S3](#mmc1){ref-type="supplementary-material"}.

To formally test whether elevated PLA~2~g1B contributed to resistance to intestinal helminth infections, we infected *Pla2g1b*^*−*/−^ mice with a variety of small- or large-intestinal helminths. Strikingly, *Pla2g1b* was essential for resistance to *H.p.*, with *Pla2g1b*^*−*/−^ mice failing to expel a 2° *H.p.* infection and retaining a patent infection ([Figures 2](#fig2){ref-type="fig"}A and 2B). The absence of PLA~2~g1B did not affect the expression of other detectable PLA~2~ family members ([Figure S1](#mmc1){ref-type="supplementary-material"}E). PLA~2~g1b was also required for expulsion of *N. brasiliensis*, which also infects the small intestine ([Figure S2](#mmc1){ref-type="supplementary-material"}A); however, *Pla2g1b* was not required for expulsion of the cecum-dwelling whipworm *Trichuris muris* ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2Type 2 Immunity Is Insufficient for Resistance to Intestinal Helminth Infection in the Absence of *Pla2g1b*(A) Luminal *H.p.* worms in the small intestine 14 days after 2° infection.(B) Fecal egg counts 14 days after 2° *H.p.* infection.(C) Frequency of *Il4*^gfp+^CD44^hi^ CD4^+^ cells in the mesenteric lymph node (mLN) and the spleen of mice 7 days after 2° infection.(D) Frequency of cytokine^+^ CD4^+^CD44^hi^ cells in the mLN of mice 7 days after 2° infection.(E) *ex vivo H.p.* antigen-specific cytokine production from the mLN of mice 7 days after 2° infection.(F) Gene expression in the small intestine of mice 7 days after 2° *H.p.* infection.(G) *H.p.* antigen-specific IgG1 in the serum from mice 7 days after 2° *H.p.* infection.(H) Mucus staining (Alcian blue-periodic acid-Schiff) of the small intestine from mice 7 days after 2° *H.p.* infection.(I) RNA-sequencing-generated transcriptional landscape of the small intestine of WT and *Pla2g1b*^*−*/−^ mice 7 days after 2° *H.p.* infection.(J) Top 10 pathways predicted to be activated 7 days after 2° *H.p.* infection (relative to strain-naive, 2-fold filter, p \< 0.05).(K) Lipid metabolism pathway predicted activation score 7 days after 2° *H.p.* infection (relative to strain-naive, 2-fold filter, p \< 0.05).Data are represented as mean ± SEM, n = 5--6, representative of at least three independent experiments; ns = not significant, ^∗^ = p \< 0.05, ^∗∗∗∗^ = p \< 0.0001 determined using a two-way ANOVA with Sidak's multiple comparison analysis or an unpaired two-tailed t test. See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

IL-4 and type 2 immune responses orchestrate many of the known anti-helminth, immune-driven expulsion pathways ([@bib14]). We therefore assessed innate and adaptive type 2 immune responses in *Pla2g1b*^*−*/−^ mice and, to our surprise, found that all measured type 2 immune responses were intact. Specifically, by crossing *Pla2g1b*^*−*/−^ mice onto an *Il4*^gfp^ reporter background or by measuring IL-4 protein by intra-cellular staining, we found that Th2 cell commitment and differentiation were equivalent between genotypes ([Figures 2](#fig2){ref-type="fig"}C and 2D). Parasite-specific, Th2-derived cytokines IL-5 and IL-13 were also comparable ([Figure 2](#fig2){ref-type="fig"}E), with no measurable difference in IFNγ^+^ or IL-17A^+^ T cells ([Figure 2](#fig2){ref-type="fig"}D). Lymphocyte populations in *Pla2g1b*^*−*/−^ mice, both at baseline and following 2° *H.p.* infection, were comparable to WT mice, including both CD4^+^ and CD8^+^ T cells, ILC2s, which support early Th2 differentiation ([@bib32]) and regulatory T cells, which inhibit type 2 immune responses ([@bib46]; [Figures S2](#mmc1){ref-type="supplementary-material"}C--S2J and [S3](#mmc1){ref-type="supplementary-material"}A). Alternatively activated macrophage-associated genes, which are also essential for immunity to *H.p.* ([@bib2]), were similar between genotypes in vivo ([Figure 2](#fig2){ref-type="fig"}F) and following polarization in vitro ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Finally, B cell frequencies and serum antibodies, including *H.p.*-specific IgG1 and IgE, which are important for preventing adult worm development ([@bib27]), were comparable between WT and *Pla2g1b*^*−*/−^ mice ([Figures 2](#fig2){ref-type="fig"}G, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D). Physiological responses---including goblet cell hyperplasia and mucus hypersecretion, which correlate with expulsion---were also comparable between WT and *Pla2g1b*^*−*/−^ mice ([Figures 2](#fig2){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}E). RNA sequencing and pathway analysis of the transcriptome of duodenal tissue from naive and infected *Pla2g1b*^*−*/−^ mice 7 days after 2° *H.p.* infection identified that the transcriptional responses and associated pathways were very similar to WT mice with the exception of 2 genes, *Pla2g1b* and *Lars2* ([Figures 2](#fig2){ref-type="fig"}I, 2J, and [S3](#mmc1){ref-type="supplementary-material"}F). To our surprise, predicted activation of lipid metabolism pathways and synthesis of bioactive lipids, including cysteine leukotrienes and prostaglandin E 2 (PGE~2~), serum fatty acid metabolites, and serum Lysophosphatidylcholines (LPC), were unaffected in *Pla2g1b*^*−*/−^ mice ([Figures 2](#fig2){ref-type="fig"}K and [S3](#mmc1){ref-type="supplementary-material"}G--S3I), most likely due to unaltered expression of other phospholipase A~2~ enzymes ([Figure S1](#mmc1){ref-type="supplementary-material"}E). These data suggest that the failure to expel *H.p.* in *Pla2g1b*^*−*/−^ mice was not due to altered lipid metabolism or known immune-mediated or stromal-associated expulsion mechanisms.

To determine the source of PLA~2~g1B and its regulation, we monitored *Pla2g1b* expression in duodenal tissue following 1° infection, 1° infection and drug cure, and 2° infection. *Pla2g1b* was significantly upregulated 14 days after drug cure of a 1° infection (day 28) and was maintained with or without a 2° infection ([Figures 3](#fig3){ref-type="fig"}A and [1](#fig1){ref-type="fig"}F). This correlated with the development and maintenance of resistance to 2° infection. Despite a strong type 2 immune response, *Pla2g1b* expression was not upregulated in mice given a 1° infection ([Figure 3](#fig3){ref-type="fig"}B) or following drug treatment alone ([Figure 3](#fig3){ref-type="fig"}C), but had a trend to be reduced. We hypothesize that a 1° *H.p.* infection may actively inhibit PLA~2~g1B through secretion of immunomodulatory proteins. However, this remains to be tested. IL-4 is essential for resistance to a 2° *H.p.* infection ([@bib40]). We therefore investigated whether IL-4 was required for upregulation of *Pla2g1b* in resistant mice. Anti-IL-4 antibody treatment prior to and during drug-treatment did not prevent *Pla2g1b* upregulation in resistant mice ([Figure 3](#fig3){ref-type="fig"}D), suggesting that *Pla2g1b* is not regulated in an IL-4 or type-2 immune dependent manner. To test whether Rag-dependent, adaptive immune cells and common gamma chain (cg)-dependent innate immune cells and signaling were required for *Pla2g1b* expression, we infected and drug-treated WT and *Rag2*^*−*/−^*cg*^*−*/−^ mice. Following drug treatment, WT, but not *Rag2*^*−*/−^*cg*^*−*/−^, mice upregulated *Pla2g1b*, indicating that at this time prior to immune-mediated active expulsion, adaptive and cg-dependent signaling was required for the upregulation of *Pla2g1b in vivo* ([Figure 3](#fig3){ref-type="fig"}E).Figure 3Intestinal *Pla2g1b* Is Regulated by the Microbiota and Rag- and Common Gamma Chain-Dependent Cells in Resistant Mice(A) Kinetics of *Pla2g1b* expression in the small intestine during *H.p.* 2° infection model.(B) Kinetics of *Pla2g1b* expression in the small intestine during *H.p.* 1° infection, n = 6.(C) *Pla2g1b* expression at day 28 (14 days post-Rx) in the small intestine, n = 5.(D) *Pla2g1b* expression at day 28 (14 days post-Rx, 1°-Rx) in the small intestine following anti-IL-4 (αIL-4) or Isotype (Iso) treatment, n = 9--10 (data pooled from two independent experiments).(E) *Pla2g1b* expression at day 28 (14 days post-Rx, 1° Rx) in the small intestine, n = 7--10 (data pooled from two independent experiments).(F) *Pla2g1b* expression at day 28 (14 days post-Rx, 1° Rx) in the small intestine following antibiotic treatment, n = 9--10 (data pooled from two independent experiments).Data are represented as mean ± SEM, n = 3. All data are representative of at least two independent experiments; ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, determined using a one-way ANOVA with Dunnett's multiple comparison analysis, unpaired t test, or a Mann-Whitney test.

To identify additional type 2 independent mechanisms of *Pla2g1b* upregulation, we tested whether the host microbiota contributed to *Pla2g1b* regulation. Antibiotic-treated mice completely failed to upregulate *Pla2g1b* ([Figure 3](#fig3){ref-type="fig"}F), indicating that intestinal microbiota are essential for elevated *Pla2g1b* expression. Intestinal microbiota changes following helminth infection ([@bib12], [@bib33], [@bib35], [@bib47]) have previously been reported. However, whether a microbiota-driven *Pla2g1b* axis has evolved to restore intestinal homeostasis and protect from small-intestine dwelling helminths is unclear.

*In situ* hybridization localized *Pla2g1b* expression to the epithelial layer following *H.p.* 2° infection ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A) rather than in the granuloma where larvae embed ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We confirmed that *Pla2g1b* was elevated in FACS-purified CD45^--^EpCam^+^ epithelial cells rather than CD45^+^EpCam^--^ cells isolated from drug-cured mice compared to naive ([Figure 4](#fig4){ref-type="fig"}B). With the recent identification of tuft cells as important in anti-helminth immunity ([@bib11], [@bib20], [@bib42]), we analyzed the expression of tuft-cell-specific markers in our RNA sequencing data from the *H.p.* challenge infection model ([Figure 1](#fig1){ref-type="fig"}A). We identified significant upregulation of the tuft cell markers *Dclk*, *Trpm5*, *Siglec5* and *Pou2f3* in resistant *H.p.* 2° infected, but not in *H.p.* 1° infected mice ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Importantly, expression of tuft cell markers, which peaked transiently following infection, did not correlate with *Pla2g1b* expression, which was upregulated following drug cure of 1° infection and maintained with or without 2° challenge infection. These data suggest that *Pla2g1b* expression was not restricted to tuft cells, or at least tuft-cell-associated gene expression. In addition, although *Pla2g1b* is abundantly expressed in the pancreas ([@bib7]), it was not differentially expressed in the pancreas following infection, drug treatment, or reinfection ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Both our findings ([Figures 2](#fig2){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}) and previous data ([@bib18], [@bib24]) suggest that PLA~2~g1B does not contribute to altered dietary phospholipid digestion at steady state or during *H.p.* infection. To determine how *Pla2g1b* was regulated in epithelial cells, we generated *ex vivo* organoid cultures ([@bib37]) and found that IL-4R signaling decreased *Pla2g1b* expression but increased the expulsion-related genes Relmβ (*Retnlb*) and *Gob5* ([@bib14], [@bib17]; [Figure 4](#fig4){ref-type="fig"}C). These data again uncouple *Pla2g1b* expression from type 2 immune pathways that drive expulsion mechanisms ([@bib2], [@bib17], [@bib40]) and suggest that type 2 immunity may negatively regulate *Pla2g1b* expression to protect host tissues from the potent effects of phospholipase enzymes ([@bib30]).Figure 4Epithelial-Cell-Derived *Pla2g1b* Is Negatively Regulated by IL-4Rα-Signaling(A) *Pla2g1b* detection by RNAScope ISH in the small intestine 7 days after 2° *H.p.* infection.(B) *Pla2g1b* expression in fluorescence-activated, cell sorted (FACS) CD45^--^EpCam^+^ and CD45^+^EpCam^−^ cells from the intestinal epithelium from naive and resistant (day 28) mice, n = 6.(C) *Pla2g1b, Retnlb*, and *Gob5* expression in intestinal organoid cultures following stimulation with rIL-4 and rIL-13.Data are represented as mean ± SEM, n = 3. All data are representative of at least two independent experiments. ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, ^∗∗∗∗^ = p \< 0.0001 determined using an unpaired t test or a Mann-Whitney test. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Other sPLA~2~ family members can degrade bacterial membranes and protect from fungal infections ([@bib4], [@bib6], [@bib22], [@bib44]). We therefore asked whether PLA~2~g1B had a direct effect on *H.p.* by treating sheathed or exsheathed L3 *H.p.* larvae (to recapitulate the status of the larvae in the small intestine after passing through the stomach) ([@bib38]) and adult *H.p.* worms with recombinant PLA~2~g1B. No effect was identified on the fitness of treated L3 larvae, isolated L4 larvae, or adult worms, as determined by ATP concentration ([Figures 5](#fig5){ref-type="fig"}A, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B). To test the infectivity and viability of PLA~2~g1B-treated L3 larvae, we infected mice with PLA~2~g1B-treated L3 larvae and found that PLA~2~g1B-treated L3 larvae could embed into the intestinal wall ([Figure 5](#fig5){ref-type="fig"}B) However, significantly fewer treated larvae developed into adulthood ([Figure 5](#fig5){ref-type="fig"}C), impacting egg recovery in the feces, although failing to reach statistical significance ([Figure S5](#mmc1){ref-type="supplementary-material"}C). PLA~2~g1B-mediated effects on L3 larvae were dependent on the catalytic activity of PLA~2~g1B as the PLA~2~ irreversible inhibitor manoalide completely abrogated the protective effect of PLA~2~g1B treatment *in vitro* ([Figure S5](#mmc1){ref-type="supplementary-material"}D).Figure 5PLA~2~g1B Has Direct Anthelmintic Properties(A) ATP concentration of *H.p.* L3 larvae after 24 hr treatment with PLA~2~g1B, n = 3.(B) Number of *H.p.* larvae imbedded in the small intestinal wall 5 days after infection following 24 hr treatment with PLA~2~g1B, n = 5.(C) Luminal *H.p.* worms in the small intestine 14 days after 1° infection following 24 hr treatment with PLA~2~g1B, n = 10 (data pooled from two independent experiments).(D) *Pla2g1b*^*−*/−^ or WT mice were orally infected with 200 L3 *H.p.* larvae on day 0 and were drug treated (Rx) on days 14 and 15. Mice were then reinfected with PLA~2~g1B-treated L3 *H.p.* larvae on day 35 and harvested 14 days after infection (2°). Another cohort of *Pla2g1b*^*−*/−^ or WT mice were orally infected with 200 L3 *H.p.* larvae on day 35 and harvested 14 days after infection (1°).(E) Luminal *H.p.* worms in the small intestine 14 days after 1° or 2° infection following 24 hr treatment with PLA~2~g1B.(F) Luminal *H.p.* worms in the small intestine 14 days after 1° infection following 24 hr treatment with PLA~2~g1B.(G) Luminal *H.p.* worms in the small intestine 14 days after 2° infection following 24 hr treatment with PLA~2~g1B.Data are represented as mean ± SEM, n = 4--5. All data re representative of at least two independent experiments. ^∗^ = p \< 0.05, ^∗∗∗^ = p \< 0.001, ^∗∗∗∗^ = p \< 0.0001 determined using a two-way ANOVA with Sidak's multiple comparison analysis, one-way ANOVA with Dunnett's multiple comparison analysis, or an unpaired two-tailed t test. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

The protective effect of PLA~2~g1B-treated L3 larvae during a 1° infection did not recapitulate the full killing, expulsion, and clearance of worms observed during 2° *H.p.* infection ([Figure 2](#fig2){ref-type="fig"}). We therefore hypothesized that, for clearance of *H.p.*, a combined PLA~2~g1B-mediated impact on larvae in concert with immune-mediated physiological responses would be required. To test this, we infected and drug cured WT and *Pla2g1b*^*−*/−^ mice to elicit robust type 2 immune responses ([Figure 2](#fig2){ref-type="fig"}) and challenged mice with vehicle- or PLA~2~g1B-treated L3 larvae (model, [Figure 5](#fig5){ref-type="fig"}D). WT mice cleared the majority of either vehicle or PLA~2~g1B-treated *H.p.* larvae. *Pla2g1b*^*−*/−^ mice failed to clear vehicle-treated L3 larvae, as expected ([Figure 2](#fig2){ref-type="fig"}). However, *H.p.* killing, expulsion, and clearance were completely rescued in *Pla2g1b*^*−*/−^ mice when L3 larvae were directly treated with PLA~2~g1B ([Figure 5](#fig5){ref-type="fig"}E), suggesting that killing and expulsion of *H.p.* requires both PLA~2~g1B-mediated effects on L3 larvae and immune-mediated expulsion mechanisms.

The requirement for a combined functional immune compartment alongside direct PLA~2~g1B-mediated action was confirmed by infecting *Rag*^*−*/−^*cg*^*−*/−^ mice with PLA~2~g1B-treated larvae. Upon 1° infection, *Rag*^*−*/−^*cg*^*−*/−^ mice fail to expel PLA~2~g1B-treated larvae, unlike WT mice ([Figure 5](#fig5){ref-type="fig"}F) These data highlight the clear requirement of a competent immune compartment for parasite expulsion. This observation was reinforced when *Rag*^*−*/−^*cg*^*−*/−^ mice that were infected, drug cured, and challenged with PLA~2~g1B-treated L3 larvae failed to expel *H.p.*, unlike WT mice ([Figure 5](#fig5){ref-type="fig"}G). It is important to note that, under these 2° challenge conditions in *Rag*^*−*/−^*cg*^*−*/−^ mice, we cannot distinguish the requirement of *Rag*^*−*/−^*cg*^*−*/−^-driven *Pla2g1b* expression (required for parasite killing) from *Rag*^*−*/−^*cg*^*−*/−^-dependent immune responses (required for expulsion).

Nevertheless, these data demonstrate that PLA~2~g1B has direct anthelminthic properties distinct from type 2 immune responses and that PLA~2~g1B is essential for intestinal helminth clearance during 2° *H.p.* infection. Furthermore, these data add to other discovered anti-microbial properties of sPLA~2~ enzymes ([@bib4], [@bib6], [@bib22], [@bib25], [@bib44]) and to the site-specific arsenal of anti-microbial responses in the small intestine ([@bib10]).

Finally, to identify the direct effects of PLA~2~g1B on *H.p.* L3 larvae, we treated larvae for 24 hr with PLA~2~g1B or control buffer and subjected the treated larvae to scanning electron microscopy (SEM) and lipid composition analysis using liquid chromatography-mass spectrometry (LC-MS). Although SEM did not reveal any structural changes or alterations in membrane integrity ([Figure S5](#mmc1){ref-type="supplementary-material"}E), LC-MS analysis identified a significantly lower phospholipid abundance in the PLA~2~g1B-treated larvae when compared to untreated controls ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Of the 1,165 apolar features detected, only 112 were significantly different following PLA~2~g1B treatment; 6 were identified as phosphatidylethanolamines (PEs) (by comparing their precursor ion and MS/MS fragments with the LipidBlast library) ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A--S6E), with each being of lower abundance in the treated larvae. We also identified a similar trend in a number of putatively identified PEs (as determined by comparison of peak retention time with other identified PEs, together with intercluster mass shifts of 28 Da (CH~2~CH~2~) and intracluster mass shifts of 2 Da, indicative of differences in double-bond number, i.e., saturation) ([Figure 6](#fig6){ref-type="fig"}B). The remaining, significantly different apolar features were seen to be both increased and decreased following PLA~2~g1B treatment; however, these features were unable to be identified (examples shown in [Figure S6](#mmc1){ref-type="supplementary-material"}F). PEs are highly abundant phospholipids found in membranes of bacteria, yeast, and mammals and are required for an array of cellular functions including membrane fusion, cytokinesis, cell division, membrane curvature, and as a substrate for subsequent products ([@bib45]). The relative reduction in PEs in PLA~2~g1B-treated *H.p.* L3 larvae provides one explanation for many putative downstream impacts on larval integrity, health, and infectivity. For example, studies in yeast and *Caenorhabditis elegans* identified that low levels of PE can cause ER stress and disrupt vesicle trafficking ([@bib43]). Whether similar effects are observed in PLA~2~g1B-treated *H.p.* are currently unclear. Another possible explanation is that reducing larval phospholipids may allow for greater immune cell recognition and larval trapping in the tissue ([@bib2], [@bib8]), although this has not been tested here.Figure 6Pla2g1b-Treatment Related Changes in Lipid AbundanceRelative abundances of phosphatidylethanolamine (PE) and other lipids extracted from PLA~2~g1B-treated (10 ng/μL) and control-treated (0 ng/μL) larvae.(A) Identified PEs. Features were regarded as "identified" by comparison of their precursor ion and MS/MS fragments with the LipidBlast library, as outlined in [Figure S1](#mmc1){ref-type="supplementary-material"}. The arrangement of fatty acid moieties on the glycerol backbone (i.e., whether in the *sn-*1 or *sn-*2 position) and the position of double bonds could not be inferred. PE 38:3 and PE 38:4 were detected as a mixture of different fatty acid moieties.(B) Putatively identified (annotated) PEs. The features could be "annotated" as PEs by comparison of peak retention time and inter-cluster mass shifts of 28 Da (CH~2~CH~2~) and intra-cluster mass shifts of 2 Da (indicative of difference in double bond number \[fatty acid saturation\]) with other, identified PEs. MS/MS could not be performed due to low abundance. Data are shown as normalized intensities expressed in arbitrary units. Data are represented as mean ± SEM, n = 3. ^∗^ = p \< 0.05. TIC: Total ion current. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Taken together, our data uncouple type 2 immune-mediated anti-helminth expulsion mechanisms from the production of host enzymes that mediate direct anti-helminth activity, which are regulated by the microbiota and require competent innate and adaptive immunity. Specifically, we highlight a previously overlooked role for epithelial-cell-derived PLA~2~g1B as an essential endogenous anthelmintic that has direct effects on invading larvae, possibly by reducing phospholipid levels. Identifying mechanisms that regulate site-specific expression of *Pla2g1b* and the functional role of phospholipids in helminths may provide avenues toward greater protection from helminth infection.

STAR★Methods {#sec3}
============

Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**In Vivo*Mab* anti-mouse IL-4 (Clone 11B11)BioXCellCat\# BE0045; RRID: [AB_1107707](nif-antibody:AB_1107707){#intref0010}In Vivo*Mab* Rat IgG1 (Clone HPRN)BioXCellCat\# BE0088; RRID: [AB_1107775](nif-antibody:AB_1107775){#intref0015}**Chemicals, Peptides, and Recombinant Proteins**Recombinant mouse PLA2g1B proteinElabscienceCat\# PKSM040953Gentamicin SulfateSigmaCat\# G3632MetronidazoleSigmaCat\# M3761Cefloxin Sodium SaltSanta Cruz BiotechnologyCat\# sc-217858Vancomycin HydrochlorideSigmaCat\# SBR00001ManoalideSanta Cruz BiotechnologyCat\# sc-200733**Critical Commercial Assays**Encore® Complete RNA-Seq Library Systems kitNuGENCat\#0311, 0312, 0333, 0334.EnzChek^®^ Phospholipase A~2~ Assay KitInvitrogenCat\#E10217CellTiter-Glo^®^ Luminescent Cell Viability ATP AssayPromegaCat\#G7571**Deposited Data**Raw and analyzed RNaseq dataThis paperGEO: [GSE102789](ncbi-geo:GSE102789){#intref0020}\
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102789](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102789){#intref0025}Metabolomics dataThis paperEMBL-EBI MetaboLights: MTBLS523 and PubMed PMID: 23109552\
<http://www.ebi.ac.uk/metabolights/MTBLS523>**Experimental Models: Organisms/Strains**Mouse: *Pla2g1b*^*−*/−^ (C57BL/6 background)David Hui, [@bib36]N/AMouse: *Pla2g1b*^*−*/−^*Il4*^gfp^ (C57BL/6 background)This PaperN/AMouse: C57BL/6The Francis Crick InstituteN/AMouse: *Rag*^--/--^*cg*^*--/--*^(C57BL/6 background)The Francis Crick InstituteN/AMouse: *Rag2*^--/--^ (C57BL/6 background)The Francis Crick InstituteN/A*Heligmosomoides polygyrus bakeri*The Francis Crick InstituteN/A*Nippostrongylus brasiliensis*London School of Hygiene and Tropical MedicineN/A*Trichuris muris*The Francis Crick InstituteN/A**Oligonucleotides***Hprt* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Pla2g1b* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Arg1* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Retnla* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Chi3l3* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Retnlb* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A*Gob5* Primers, see [Table S4](#mmc1){ref-type="supplementary-material"}.This paperN/A**Software and Algorithms**FastQCBabraham Bioinformatics[www.bioinformatics.babraham.ac.uk/projects/fastqc](http://www.bioinformatics.babraham.ac.uk/projects/fastqc){#intref0035}TrimmomaticN/A<http://www.usadellab.org/cms/index.php?page=trimmomatic>Tophat2N/A<http://ccb.jhu.edu/software/tophat>Ingenuity Pathway Analysis^®^ (IPA^®^)QIAGENN/AXcalibur 3.0.63Thermo Fisher-ScientificN/AProgenesisNonlinear DynamicsN/ACEU Mass MediatorCEMBIO, Universidad San Pablo<http://ceumass.eps.uspceu.es/mediator/>**Other**mm10 (Ensembl version 75)EnsemblN/A

Contact for Reagent and Resource Sharing {#sec3.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mark Wilson (<wilson.mark@gene.com>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Animal Strains {#sec3.3.1}

All mice used in this study were maintained under specific pathogen-free conditions at the Mill Hill Laboratory, The Francis Crick Institute (London, UK). C57BL/6, *Pla2g1b*^*−*/−^ ([@bib36]), 4get ([@bib29]), *Rag*^--/--^*cg*^*--/--*^ and *Rag2*^--/--^ mice were bred and maintained at The Francis Crick Institute. *Pla2g1b*^*−*/−^*Il4*^gfp^ mice were generated by crossing *Pla2g1b*^*−*/−^ and 4get mice at The Francis Crick Institute. All mice used were male and between 6-12 weeks old at the start of the experiment and were not involved in any previous procedures. Animal experiments were performed according to institutional guidelines and following UK Home Office regulations (project license 70/8809) and were approved by The Francis Crick Institute Ethical Review Panel.

### Organoid Culture {#sec3.3.2}

Mouse organoids were established and maintained at 37°C as three-dimensional spheroid culture in Matrigel (R&D system) from isolated crypts collected from the duodenum of male C57BL/6 mice. The basic culture medium (ENR) contained advanced DMEM/F12 supplemented with penicillin/streptomycin, 10 mM HEPES, 2mM Glutamax, B27 (all from Life Technologies) and 1cmM N-acetylcysteine (Sigma) supplemented with murine recombinant EGF (life technologies), R-spondin1-CM (Trevigen) (10% final volume) and Noggin-CM (kindly provided by Dr. Hans Clevers, Hubrecht Institute, Utrecht, the Netherlands) (20% v/v). Wnt3a-CM was used at 50% (v/v) for 7 days at the beginning of the culture, then withdrawn. Organoids were stimulated with 20 ng/mL IL-4 (R&D) and 20ng/mL IL-13 (R&D) for 48 hr. RNA was extracted and qRT-PCR performed as described below.

### Bone Marrow-derived Macrophage (BMDM) Culture and Stimulation {#sec3.3.3}

Bone marrow was isolated from the femur and tibia of mice and the red blood cells were lysed with ACK lysis buffer (GIBCO). The remaining cells were then cultured in DMEM (GIBCO) (with 20% L929 cell media (in-house preparation), 10% FCS (Invitrogen), 1% L-Glutamine (GIBCO), 100 U/mL Penicillin and 100 μg/mL Streptomycin (GIBCO), 10 mM HEPES (Lonza) and 0.05mM 2-mercaptoethanol (GIBCO)) in 10mls at a density of 5x10^5^ cells/ml at 37°C. After 7 days of culture non-adhesive cells were removed before removing adherent BMDMs using 2.5mM edta (Invitrogen) in PBS (GIBCO) with 5% FCS (Invitrogen). Adherent BMDMS were washed and resuspended in DMEM (with 1% FCS (Invitrogen), 1% L-Glutamine (GIBCO), 100 U/mL Penicillin and 100 μg/mL Streptomycin (GIBCO), 10 μM HEPES (Lonza) and 0.05mM 2-mercaptoethanol (GIBCO)). Adherent BMDMs were then plated at a density of 2x10^6^ cells/ml for 24 hr. The adherent BMDMs were then stimulated for 24 hr with either 20ng/ml IL-4 (R&D) and 20ng/ml IL-13 (R&D) before RNA extraction.

Method Details {#sec3.4}
--------------

### Parasite Infections and PLA~2~g1B Treatment {#sec3.4.1}

#### Heligmosomoides polygyrus bakeri {#sec3.4.1.1}

Mice were infected with 200 L3 infective *H. polygyrus* larvae *(p.o.*) on day 0 (1° infection). Mice were drug cured (Rx) with the anthelminthic drug Pyrantel Embonate (2.5 mg/dose, Pfizer) *(p.o.*) on days 14 and 15. Mice were secondary (2°) challenge infected on day 35 or day 56 with 200 L3 infective *H. polygyrus* larvae *(p.o.*). *H. polygyrus* worms were counted in the wall of the intestine at day 5 post infection and luminal worms were counted 14 days-post 1° or 2° infection.

#### Nippostrongylus brasiliensis {#sec3.4.1.2}

Mice were infected with 350 L3 infective *N. brasiliensis larvae* (*s.c.*) on day 0. Luminal *N. brasiliensis* worms were counted on day 8.

#### Trichuris muris {#sec3.4.1.3}

Mice were infected with 200 embryonated *T. muris* eggs (*p.o.*) on day 0. Luminal *T. muris* worms were counted on day 35. For PLA~2~g1B treatment, infective L3 *H. polygyrus* larvae were exsheathed as previously described ([@bib38]). Briefly, 0.85% w/v NaCl (in distilled water) was bubbled with 40% CO~2~ in Nitrogen for 5 min, the tube was then sealed and incubated in a 37°C waterbath for a further 5 min. The pH was adjusted to pH2 using HCl and 5 mL was added to 30000-50000 L3 larvae before bubbling with 40% CO~2~ in Nitrogen for 30 s. The tube was then sealed and incubated in a 37°C waterbath for a further 30 min. Exsheathed L3 larvae were washed and counted before treatment with PLA~2~g1B. 8000 exsheathed L3 *H. polygyrus* larvae were treated with recombinant mouse PLA~2~g1B (Elabscience), recombinant mouse PLA~2~g1B plus manoalide (200 ng/μL final concentration, Santa Cruz Biotechnology) or heat inactivated recombinant mouse PLA~2~g1B in 1mL EnzChek^®^ PLA~2~ reaction buffer (Invitrogen) at room temperature for 24 hr. Recombinant mouse PLA~2~g1B was heat inactivated by heating at 100°C for 4 hr. Following treatment, larvae were washed with MilliQ water prior to use in ATP assay (detailed below) or infection. Adult L5 *H. polygyrus* worms were isolated from C57BL/6 following primary infection between days 14 and 28 using a modified Baermann apparatus. Adult L5 *H. polygyrus* worms were treated with recombinant mouse PLA~2~g1B (Creative Biomart) or heat inactivated recombinant mouse PLA~2~g1B in EnzChek^®^ PLA~2~ reaction buffer (Invitrogen) at room temperature for 24 hr.

### ATP Assay {#sec3.4.2}

The ATP of infective L3 *H. polygyrus* larvae, L4 *H. polygyrus* larvae (removed from intestinal wall at day 7 post infection) and adult L5 *H. polygyrus* worms was measured using the CellTiter-Glo^®^ Luminescent Cell Viability Assay (Promega). Briefly, *H. polygyrus* adult worms, two L4 larvae or 100 L3 larvae were homogenized using a motorised pestle in 110 μL of PBS and 110 μL of CellTiter-Glo^®^ Reagent. The homogenate was incubated for 10 min at room temperature before centrifugation at 1000 g for 3 min. 200 μL of the supernatant was transferred to a 96 well opaque-walled plate and incubated for 10 min at room temperature before recording luminescence. An ATP standard curve was generated by using recombinant ATP (Promega) as detailed in the CellTiter-Glo^®^ Luminescent Cell Viability Assay instructions.

### Antibiotic Treatment {#sec3.4.3}

The antibiotics Gentamicin sulfate salt (1 mg/mL, Sigma), Metronidazole (1 mg/mL, Sigma), Cefloxin sodium salt (1 mg/mL, Santa Cruz Biotechnology), Vancomycin hydrochloride (1 mg/mL, Sigma) were administered in the drinking water. Treatment was started 7 days prior to 1° *H. polygyrus* infection and maintained throughout the duration of the experiment.

### Antibody Treatment {#sec3.4.4}

Anti-IL-4 antibody (0.5 mg/dose, BioXcell) was administered *i.p.* on days 13, 15, 17, 19 and 21 after 1° *H.* polygyrus infection. Mice were drug cured (Rx) with the anthelminthic drug Pyrantel Embonate (2.5 mg/dose, Pfizer) *(p.o.*) on days 14 and 15.

### Histology, In Situ Hybridization {#sec3.4.5}

Small intestinal tissue was removed and fixed in 4% formaldehyde for 24 hr then washed in 70% ethanol. The tissues were embedded in paraffin, and sectioned. Sections were stained with hematoxylin and eosin stain or Alcian blue/ periodic acid-Schiff stain. *Pla2g1b* Staining: *Pla2g1b* RNAscope^®^ probes were designed by Advanced Cell Diagnostics and in situ hybridization was performed with RNAscope^®^ 2.5 Reagent Kit Brown (Advanced Cell Diagnostics), following the manufacturer's instructions. The final *Pla2g1b* signal was detected chromogenically using DAB and the sections were counterstained with Haematoxylin Stained. Stained slides were scanned with a VS120-SL slide scanner (Olympus, Tokyo, Japan) and images were captured with the OlyVIA image viewer (Olympus).

### RNA Sequencing and Analysis {#sec3.4.6}

RNA was extracted using the QIAGEN® miRNeasy Mini Kit, following the manufacturer's instructions. RNA integrity was confirmed using Agilent's 2100 Bioanalyser. Total RNA libraries were created using the Encore® Complete RNA-Seq Library Systems kit (NuGEN), following manufacturer's instructions. Total RNA libraries were sequenced using the Illumina® HiSeq 2500. The raw Illumina reads were analyzed as follows. First, the data quality was analyzed using FastQC ([www.bioinformatics.babraham.ac.uk/projects/fastqc](http://www.bioinformatics.babraham.ac.uk/projects/fastqc){#intref0060}). Then the low quality bases were trimmed using Trimmomatic. The read pairs which passed the trimming quality filters were then aligned to mm10 (Ensembl version 75) using Tophat2. Counts were determined using htseq_count. Normalization and statistical analysis was performed using edgeR. Differential gene analysis was calculated from naive control group. Statistically significant genes with FDR \< 0.05 are reported. Ingenuity Pathway Analysis^®^ (IPA^®^): RNA sequencing datasets were uploaded to IPA® where fold change filters and pathway analysis algorithms were applied. Ratio of ratios plots were generated from the ratio of expression of genes from *H.p.* 2° to *H.p.* 1° (relative to naive, 2-fold filter, p \< 0.05) (y axis) against the fold-change of each gene in both compared to naive (2-fold filter, p \< 0.05) (x axis).

### Quantitative Real-time Polymerase Chain Reaction {#sec3.4.7}

RNA was extracted and purified from tissue or cells as described above. Reverse transcription was performed with 0.1-1 μg RNA using QIAGEN® Quantitect RT Kit following manufacturer's instructions to create cDNA. Generated cDNA was used for quantitative real-time PCR analysis using Power SYBR® Green PCR Master Mix (Applied Biosystems) and quantified on the 7900HT (Applied Biosystems). Where appropriate, relative gene expression was determined via normalization to the housekeeping gene *Hprt* and the relevant control group (see Figure legends and [Table S4](#mmc1){ref-type="supplementary-material"}).

### PLA~2~ Activity Assay {#sec3.4.8}

PLA~2~ activity was determined using EnzChek^®^ Phospholipase A~2~ Assay Kit (Invitrogen), following manufactures instructions. Briefly, approximately 1cm of duodenal tissue was removed and homogenized in 300 μL of cOmplete protease inhibitor (Roche) before centrifugation. 25 μL of the supernatant was transferred to a 96 XXX well plate with 25 μL of the substrate-liposome mix then incubated at room temperature in the dark for 10 min. Fluorescence emission was measured at 515nm and reported after blank reduction.

### Cell Isolation {#sec3.4.9}

The spleen, mLNs and thymus were made into single-cell suspensions by gently mashing through a 40 micron filter (Thermo-Scientific, Loughborough, UK), and the red blood cells were lysed from the spleen single cell suspension with ACK lysis buffer (GIBCO). Single cell suspensions were used for *ex* vivo restimulations and flow cytometry analysis. For the isolation of small intestinal epithelial cells: adipose tissue was removed from the small intestine dissected longitudinally to remove faecal contents, and cut into 2cm segments. The epithelial layer was then dissociated by in incubating the intestine segments in PBS containing 10% FBS, 15cmm HEPES, 5cmm EDTA (Life Technologies, Paisley, UK), and 1cmm dithiothreitol (Sigma, Gillingham, UK) for 30cminutes at 37c°C. The remaining intestinal tissue was removed using a wide mesh sieve and epithelial layer was retained. Cells were layered onto 20% isotonic Percoll (GE Healthcare, Little Chalfont, UK) to remove debris. Cells were then resuspended in cIMDM (complete Iscove's Modified Dulbecco's Medium (cIMDM) containing 1% fetal bovine serum (FBS), 1mM EDTA, 100U/ml Penicillin (GIBCO) and 100 μg/ml Streptomycin (GIBCO), 8mM L-glutamine (GIBCO) and 0.05mM 2-mercaptoethanol (GIBCO)) and prepared for cell sorting.

### Flow Cytometry and Cell Sorting {#sec3.4.10}

Cell sorting was performed using a MoFlo XDP cell sorter (Beckman Coulter). Cell suspensions were stained for 25 min with antibodies in PBS with 1% FCS. To prepare for sorting, stained cells were diluted in phenol-red free IMDM (GIBCO) (with 1% FCS, 2mM EDTA (Invitrogen), 100 U/mL Penicillin and 100 μg/mL Streptomycin (GIBCO), 8 mM L-glutamine (GIBCO), and 0.05 mM 2-mercaptoethanol (GIBCO)). For flow cytometry analysis, cells were analyzed using a BD LSRFortessa X-20 (BD Biosciences) or BD LSRII (BD Biosciences) and data were analyzed using FlowJo software (Version 10, Treestar Inc). Cells were sometimes fixed in 2%--4% paraformaldehyde for FACS analysis. For cell sorting, viability of the cells was determined using Propidium Iodide (Sigma); for analysis, viability of the cells was determined using the LIVE/DEAD Fixable Blue kit (Life Technologies). Antibodies used include: CD3 (145-2C11; APC, (BioLegend)), CD4 (RM4-5; BV605, efluor450 (eBioscience), APC (BioLegend)), CD8 (53-6.7; PE-Cy7, APC (BioLegend)), CD11c (N418; APC (BioLegend)), CD11b (M1/70; APC (BioLegend)), CD19 (1D3; efluor450 (eBioscience)), CD19 (6D5; APC (BioLegend)), CD25 (PC61; APC-Cy7 (BioLegend), APC (eBioscience)), CD44 (IM7; Percpcy5.5 (eBioscience)), CD45 (30-F11; FITC (Bioscience)), CD49b (DX5; APC (BioLegend)), CD62L (MEL-14; APC (eBioscience)), CD69 (H1.2F3; PE (BioLegend)), EpCam (G8.8; APC (eBioscience), Foxp3 (FJK-16S; PE (eBioscience)), Gr1 (RB68C5; APC (BioLegend)), IFNγ (XMG1.2; PE (BD Bioscience)), IL4 (PE, 11B11, eBioscience)), IL17a (17B7; PE-Cy7 (eBioscience)), KLRG1 (2F1; PerCpefluor710 (eBioscience)), NK1.1 (PK136; APC (BioLegend)), Sca1 (E13-161.7; PB (eBioscience)), TCRγδ (GL3; APC (BioLegend)), TCRαβ (H57-597; APC (eBioscience)), TCRβ (H57-597; Percpcy5.5 (BioLegend)), Ter119 (TER-119; APC (BioLegend)), Thy1.2 (53-2.1; PE-Cy7 (BioLegend)). All staining was performed in the presence of FcR Blocking Reagent (Miltenyi Biotec). Intracellular cytokine staining (ICS) was performed following 6 hr of re-stimulation with 50ng/mL phorbol 12-myristate 13-acetate (PMA, Promega) and 1 μg/mL ionomycin (Sigma) and BD Golgi Stop and BD Golgi Plug (diluted 1:1000, BD Biosciences). Following surface stain, cells were incubated with eBioscience Fixation/Permeabilization buffer for 25 min followed by 25 min in Permeabilization buffer (eBioscience), and incubation with antibodies in Permeabilization buffer for a further 30 min. ILCs were analyzed using the following strategy: Live, lymphocytes, CD45^+^, Lineage^--^ (CD3, CD4, CD8, CD19, CD11c, CD11b, NK1.1, TCRβ, TCRγδ, Gr-1, CD49b, Ter119), Thy1.2^+^, KLRG1^+^, and Sca1^+^.

Tregs were analyzed using the following gating strategy: Live, lymphocytes, CD4^+^, TCRβ^+^, CD25^+^ and Foxp3^+^. Epithelial cells were sorted using the following gating strategy: Live, CD45^--^ and EpCam^+^.

### Ex Vivo Stimulations {#sec3.4.11}

mLNs were harvested and processed as above. Cells were plated at 2x10^5^ cells per 200μl with 10μg/ml of *H. polygyrus* antigen extract (HEX). Supernatant was harvested after 4 days. Cytokines were detected in the supernatant using ELISAs.

### ELISAs {#sec3.4.12}

IFNγ, IL-5 and IL-13 were measured using DuoSet ELISA kits, according to the manufacturer's instructions (R&D). Cysteinyl leukotrienes and prostaglandin E~2~ were measured in small intestinal homogenate (see above) using ELISA kits, according to manufacturer's instructions (Enzo), and normalized to total protein content. Total IgE ELISA was performed by coating with Purified Rat Anti-Mouse IgE (R35-72, BD PharMingen) at 2 μg/mL overnight, followed by overnight incubation with serum and standard (Purified Mouse IgE,k isotype Standard, BD PharMingen), and detection with Biotin Rat Anti-Mouse IgE at 1 μg/mL (R35-118, BD PharMingen), Streptavidin HRP at 1:000 (BD PharMingen) and ABTS One Component HRP Microwell Substrate (SurModics). *H*. *polygyrus-*specific IgG1 was detected by coating plates with 5 μg/mL *H*. *polygyrus* antigen overnight, followed by overnight incubation with serially diluted serum and detection with Biotin Rat Anti-Mouse IgG1 (Invitrogen) and streptavidin and ABTS, as above.

### Scanning Electron Microscopy (SEM) {#sec3.4.13}

*H. polygyrus* larvae were dehydrated stepwise in ethanol (2 × 5 min in 70, 90 and 100% ethanol) before transferring to 100% acetone (2 × 5 min). Larvae were critical point dried from 100% Ethanol in a CPD300 critical point drier (Leica Microsystems UK), mounted on a carbon sticky pad on a stub, sputter-coated with 5 nm of platinum, and imaged in a Phenom ProX benchtop scanning electron microscope (Phenom-World) with a secondary electron detector.

### Serum Chemistry {#sec3.4.14}

Whole blood was collected from mice and the serum separated after clotting. The serum was sent to the MRC Harwell Institute (UK) for metabolite analysis. Lysophosphatidylcholine (LPC) was measured using the AZWELL LPC Assay Kit according to the manufacturer's instructions (Cosmo Bio).

### Lipid Extraction and Analysis {#sec3.4.15}

Lipids were extracted from *H. polygyrus* L3 larvae using a method adapted from a previous publication ([@bib28]). Following PLA~2~g1B treatment ∼8000 *H. polygyrus* larvae were washed three times with MilliQ water, resuspended in 2 mL methanol and heated in a sealed tube under nitrogen at 55°C for 20 min. After cooling, 4 mL chloroform was added and the sample was agitated with a magnetic stirrer for 3 hr. The organic phase was removed and the residue ground (using a glass homogenizer) and extracted with 2 mL chloroform/methanol (2:1, v/v) for 2 hr.

For LC-MS, lipids were dried under nitrogen and redissolved in 100 μL of methanol/chloroform (1:1 v/v) and diluted 1:2 with solvent A (hexane:isopropanol, 70:30 \[v: v\], 0.02% \[m/v\] formic acid, 0.01% \[m/v\] ammonium hydroxide), centrifuged at 1,500 rpm for 5 min to remove trace non-lipidic materials prior to transfer to a glass autosampler vial (Agilent). 10 μL was injected onto a BETASIL diol column (5 um x 150 mm x 2.1 mm, with BETASIL diol guard column (10 mm x 2.1 mm), held at 20°C) in an Ultimate 3000 HPLC system coupled to a Thermo Exactive Plus Orbitrap MSfor full scan or Q Exactive Orbitrap MS for MS/MS scan. Lipids were eluted at 0.15 ml/min with a binary gradient from 0% to 100% solvent B (isopropanol:methanol, 70:30 \[v/v\], 0.02% \[m/v\] formic acid, 0.01% \[m/v\] ammonium hydroxide): 0--10 min, 0% B; 17--22 min, 50% B; 30--35 min, 100% B; 40--44 min, 0% B, followed by additional 6 min 0% B post-run. MS data were acquired in both polarities using a full scan method. The positive and negative HESI-II spray voltages were 4.5 and 3.5 kV, respectively; the heated capillary temperature was 250°C; the sheath gas pressure was 30 psi; the auxiliary gas setting was 20 psi; and the heated vaporizer temperature was 150°C. Both the sheath gas and the auxiliary gas were nitrogen. The parameters of the full mass scan were as follows: a resolution of 70,000, an auto gain control target under 3 × 10^6^, a maximum isolation time of 200 ms, and an m/*z* range 200--3000. To confirm the identification of significant features, samples were re-ran in parallel reaction monitoring (PRM\_ mode, parameters as follows: a resolution of 17,500, an auto gain control target under 2 × 10^5^, a maximum isolation time of 100 ms, an isolation window of m/*z* 0.4 and normalized collision energy were optimized for each feature individually. Data were acquired using Xcalibur 3.0.63 (Thermo Fisher Scientific) and Progenesis (Nonlinear Dynamics) was used for data alignment and peak detection. Data were normalized against the total ion abundance.

Annotations were assigned to accurate masses with a maximum error of 5 ppm using Metlin, LipidMaps, Kegg and HMDB which were searched simultaneously using the CEU Mass Mediator engine (<http://ceumass.eps.uspceu.es/mediator/>).

### Experimental Design {#sec3.4.16}

All experiments contained at least three biological replicates and are representative of at least two independent experiments (see figure legends for exact values). No strategy was employed for randomization, sample size estimation or data inclusion/exclusion criteria. The studies performed were also not blinded at any stage.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

All statistical analysis for biological data was performed using GraphPad Prism (v6.02). Data was analyzed, where appropriate, with either an unpaired two-tailed t test, One-way ANOVA (Dunnett's multiple comparison analysis), Two-way ANOVA (Sidak's multiple comparison analysis) or Mann-Whitney test. n represents the number of biological replicates. Please see figure legends for statistical tests used and exact value of n. No methods were used to confirm whether the data met assumptions of the statistical approach used. Values are reported as the means ± SEM. ^∗^ = p \< 0.05, ^∗∗^ = p \< 0.01, ^∗∗∗^ = p \< 0.001 and ^∗∗∗∗^ = p \< 0.0001.

Data and Software Availability {#sec3.6}
------------------------------

The raw and analyzed RNA sequencing data files have been deposited in the NCBI Gene Expression Omnibus database under ID code GEO: [GSE102789](ncbi-geo:GSE102789){#intref0070}. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102789>

LC-MS metabolomics data have been deposited in the EMBL-EBI MetaboLights database under ID code MTBLS523 and PubMed PMID: 23109552. <http://www.ebi.ac.uk/metabolights/MTBLS523>
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